Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + carboplatin + maintenance letrozole versus letrozole monotherapy in primary low-grade serous ovarian or peritoneal carcinoma
2022-002877-27Phase 3Active
- Sponsor
- Cancer Trials Ireland
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Serous Papillary Cystadenocarcinoma and serous peritoneal carcinoma (PPSC) comparing Paclitaxel + carboplatin followed by maintenance letrozole with Letrozole monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Jan 2023; status: active.
02
Drugs
letrozolepaclitaxelcarboplatin
03
Conditions
Serous Papillary Cystadenocarcinomaserous peritoneal carcinoma (PPSC)
Beyond the preview
Go deeper on 2022-002877-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002877-27.